Skip to main content

Advertisement

SpringerLink
Log in

Erlotinib-related rhabdomyolysis: the role of pharmacogenetics and drug–drug interaction

  • Letter to the Editor
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Reck M, Popat S, Reinmuth N, De Ruysscher D, Kerr KM, Peters S (2014) Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii27–iii39

    Article  PubMed  Google Scholar 

  2. Steins M, Thomas M, Geißler M (2014) Erlotinib. Recent Results Cancer Res 201:109–123

    Article  CAS  PubMed  Google Scholar 

  3. Gridelli C, Maione P, Bareschino MA, Schettino C, Sacco PC, Ambrosio R et al (2010) Erlotinib in the treatment of non-small cell lung cancer: current status and future developments. Anticancer Res 30(4):1301–1310

    CAS  PubMed  Google Scholar 

  4. Tiseo M, Andreoli R, Gelsomino F, Mozzoni P, Azzoni C, Bartolotti M et al (2014) Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer 83(2):265–271

    Article  PubMed  Google Scholar 

  5. SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R (2008) SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 359(8):789–799

    Article  Google Scholar 

  6. Zimmerman JL, Shen MC (2013) Rhabdomyolysis. Chest 144(3):1058–1065

    Article  CAS  PubMed  Google Scholar 

  7. Mirrakhimov AE, Mirrakhimov EM (2014) Rhabdomyolysis: some extra clues to diagnosis. Chest 145(2):415–416

    Article  PubMed  Google Scholar 

  8. Neyra JA, Rocha NA, Bhargava R, Vaidya OU, Hendricks AR, Rodan AR (2015) Rhabdomyolysis-induced acute kidney injury in a cancer patient exposed to denosumab and abiraterone: a case report. BMC Nephrol 16:118. doi:10.1186/s12882-015-0113-6

    Article  PubMed Central  PubMed  Google Scholar 

  9. Moscetti L, Nelli F, Ruggeri EM (2011) Rhabdomyolysis from erlotinib: a case report. Tumori 97(3):415–416

    PubMed  Google Scholar 

  10. Panel N, Blay JY, Adenis A (2008) Imatinib as a possible cause of severe rhabdomyolysis. N Engl J Med 358:2746–2747

    Article  Google Scholar 

  11. Marchetti S, de Vries NA, Buckle T, Bolijn MJ, van Eijndhoven MA, Beijnen JH et al (2008) Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Mol Cancer Ther 7(8):2280–2287

    Article  CAS  PubMed  Google Scholar 

  12. Lainey E, Sébert M, Thépot S, Scoazec M, Bouteloup C, Leroy C et al (2012) Erlotinib antagonizes ABC transporters in acute myeloid leukemia. Cell Cycle 11(21):4079–4092

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Hamada A, Sasaki J, Saeki S, Iwamoto N, Inaba M, Ushijima S et al (2012) Association of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non-small-cell lung cancer. Pharmacogenomics 13(5):615–624

    Article  CAS  PubMed  Google Scholar 

  14. Karch FE, Lasagna L (1975) Adverse drug reactions—a critical review. JAMA 234(12):1236–1241

    Article  CAS  PubMed  Google Scholar 

  15. van Erp NP, Eechoute K, van der Veldt AA, Haanen JB, Reyners AK, Mathijssen RH, Boven E, van der Straaten T, Baak-Pablo RF, Wessels JA, Guchelaar HJ, Gelderblom H (2009) Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol 27(26):4406–4412

    Article  PubMed  Google Scholar 

  16. Gurney H, Wong M, Balleine RL, Rivory LP, McLachlan AJ, Hoskins JM, Wilcken N, Clarke CL, Mann GJ, Collins M, Delforce SE, Lynch K, Schran H (2007) Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. Clin Pharmacol Ther 82(1):33–40

    Article  CAS  PubMed  Google Scholar 

  17. Zwisler ST, Enggaard TP, Noehr-Jensen L, Mikkelsen S, Verstuyft C, Becquemont L, Sindrup SH, Brosen K (2010) The antinociceptive effect and adverse drug reactions of oxycodone in human experimental pain in relation to genetic variations in the OPRM1 and ABCB1 genes. Fundam Clin Pharmacol 24(4):517–524

    Article  CAS  PubMed  Google Scholar 

  18. Bowlin SJ, Xia F, Wang W, Robinson KD, Stanek EJ (2013) Twelve-month frequency of drug-metabolizing enzyme and transporter-based drug–drug interaction potential in patients receiving oral enzyme-targeted kinase inhibitor antineoplastic agents. Mayo Clin Proc 88(2):139–148

    Article  CAS  PubMed  Google Scholar 

  19. Shi Z, Peng XX, Kim IW, Shukla S, Si QS, Robey RW, Bates SE, Shen T, Ashby CR Jr, Fu LW, Ambudkar SV, Chen ZS (2007) Erlotinib (Tarceva, OSI-774)antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res 67(22):11012–11020

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinic for Lung Diseases Jordanovac, University Hospital Centre Zagreb, Jordanovac 104, 10000, Zagreb, Croatia

    Marta Koršić, Davorka Muršić, Sonja Badovinac, Mihovil Roglić, Marko Jakopović & Branka Čučević

  2. Clinical Institute of Laboratory Diagnosis, University Hospital Centre Zagreb, Kišpatićeva 12, 10000, Zagreb, Croatia

    Nada Božina

Authors
  1. Marta Koršić
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Davorka Muršić
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sonja Badovinac
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nada Božina
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mihovil Roglić
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marko Jakopović
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Branka Čučević
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Davorka Muršić.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Koršić, M., Muršić, D., Badovinac, S. et al. Erlotinib-related rhabdomyolysis: the role of pharmacogenetics and drug–drug interaction. Cancer Chemother Pharmacol 76, 1317–1319 (2015). https://doi.org/10.1007/s00280-015-2885-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-015-2885-6

Keywords

Search

Navigation